SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|Item 7.01||Regulation FD Disclosure.|
On January 11, 2021, Idera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Vincent Milano, Chief Executive Officer of the Company, will be presenting virtually at two upcoming investor conferences. Mr. Milano will review the Company’s recent achievements, current progress and expected 2021 milestones.
|·||HCW Wainwright Bioconnect Conference. Mr. Milano, together with Dr. Elizabeth Tarka, Chief Medical Officer of the Company and Mr. John Kirby, Chief Financial Officer of the Company, will be participating in a virtual fireside chat at the HCW Wainwright Bioconnect Conference. For those registered for the conference, a video will be available on-demand during the week of January 11-14, 2021. The Company will also post the video on its website at 6 AM Eastern on Monday, January 11, 2021, which can be accessed via Investor Relations section of the Company’s website at https://ir.iderapharma.com/.|
|·||39th Annual JPMorgan Healthcare Conference. On January 13, 2021, Mr. Milano will be presenting at the 39th Annual JPMorgan Healthcare Conference at 3:40 PM Eastern Time. A live audio webcast of the presentation on the Investor Relations section of the Company’s website at https://ir.iderapharma.com/.|
The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press release dated January 11, 2021.|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|IDERA PHARMACEUTICALS, INC.|
|Dated: January 11, 2021||By:||/s/ Bryant D. Lim|
|Bryant D. Lim|
|Senior V.P., General Counsel|
Idera Pharmaceuticals to Present at Upcoming Conferences
EXTON, PA, January 11, 2021 — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.
“2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod, the most advanced TLR9 agonist therapy in development, can offer meaningful alternatives to patients suffering from advanced anti-PD-1 refractory melanoma and, potentially, colorectal cancer,” stated Vincent Milano, Idera’s Chief Executive Officer. “We’re looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.”
Continued Mr. Milano, “Our entire team is driven by our goal of making a difference for patients and is unified in its persistence to help ensure the quality of our clinical results, NDA and commercial readiness, and a strong financial outlook that includes existing cash that is expected to take us into the first quarter of 2022. We have confidence that this is the year Idera will deliver on its long history of innovative science and begin to turn that history into a business reality.”
The Company plans to share further corporate and ILLUMINATE program updates at the following conferences in January:
|-||39th Annual J.P. Morgan Healthcare Conference,
January 11-14, 2021
Presentation on January 13, 2021, 3:40 pm EST
|-||H.C. Wainwright BioConnect 2021 Conference, January 11-14, 2021|
Pre-recorded conversation available January 11, 2021, 6:00 am EST
Live and archived webcasts of the investor conference presentations will be available in the Investor Relations section of the Idera website.
About Idera Pharmaceuticals
Harnessing the approach of the earliest researchers in immunotherapy and the company’s vast experience in developing proprietary immunology platforms, Idera’s development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs. To learn more about Idera, visit www.iderapharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company's strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, clinical trials, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether the Company’s cash resources will be sufficient to fund the Company’s continuing operations and the further development of the Company’s programs for the period anticipated; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of the results that will be generated in future clinical trials, including in clinical trials in different disease indications; whether products based on Idera's technology will advance into or through the clinical trial process when anticipated or at all or warrant submission for regulatory approval; whether such products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations will be successful; and such other important factors as are set forth under the caption "Risk factors" in the Company’s Annual Report filed on Form 10-K for the period ended December 31, 2019 and the Company’s Quarterly Report filed on Form 10-Q for the period ended September 30, 2020. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Idera Pharmaceuticals Contacts:
|Jill Conwell||John J. Kirby|
|Investor Relations &||Chief Financial Officer|
|Corporate Communications||Phone (484) 348-1627|
|Phone (484) 348-1675||JKirby@IderaPharma.com|